Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
- 9/6/2011
Jennerex's Virus-Based Drug Targets & Infects Tumors Jennerex, Inc. recently announced the publication of clinical data on its lead product...- 10/17/2011
Oncobiologics Announces Two New Agreements Worth Almost $80 Million Oncobiologics recently announced it has signed two major agreements. The first...- 4/3/2012
Aptar Pharma's Device Delivers INSYS Therapeutics' Drug Aptar Pharma recently announced INSYS Therapeutics' SUBSYS, which uses an Aptar Pharma Sublingual...- Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical’s Adjuvant
Vical Incorporated recently announced researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin-formulated DNA vaccine candidate...- 4/17/2012
Ei Increases Capabilities Through New Partnership Ei, A Pharmaceutical SolutionWorks, recently announced a new partnership with KeraNetics. Ei has begun...- 5/16/2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal...- 7/18/2012
Prokarium Acquires Key Oral Vaccine Technology Prokarium Ltd recently announced it completed a key technology acquisition from Emergent BioSolutions Inc....- Prokarium Acquires Key Oral Vaccine Technology
Prokarium Ltd recently announced it completed a key technology acquisition from Emergent BioSolutions Inc. The technology includes Emergent's live Salmonella-based...- SPECIAL FEATURE: Handheld Injection Devices: Safer, Simpler, and More Customized
In this exclusive Drug Development & Delivery annual report, handheld injection experts provide their thoughts about the various factors backing the adoption of the devices including ease of use, pain-free delivery, and differentiation for product line extensions.
- 1/23/2012
Amgen Invests $200 Million in Monoclonal Antibodies Amgen recently announced plans to build a new manufacturing facility in the Tuas...- 3/6/2013
Capsugel Announces Major Acquisition Capsugel recently announced it has acquired Encap Drug Delivery. Based in Scotland, Encap's focus on liquid and...- Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement
Althea Technologies, Inc. and Profectus BioSciences Inc. recently announced the signing of a manufacturing supply agreement for plasmid DNA...- DELIVERY DEVICES – The New Industry Paradigm for Prefilled Success
Alan Shortall indicates that following a period of relative industry stability defined by peripheral innovation, a converging series of external and internal forces are set to reshape the prefilled syringe industry so that it will better serve the emerging needs of pharmaceutical companies, patients, and other stakeholders across the continuum of care.
- FORMULATION DEVELOPMENT – Trends & Opportunities in Particle Design Technologies – Life Sciences & Biopharma in the Spotlight
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical industry.
- Inovio’s Delivery Technology Powers Durable, Best-in-Class T-Cell Responses From HIV Vaccine
Inovio Pharmaceuticals, Inc. recently announced the peer-reviewed publication of results from two Phase I trials (HVTN 070 and HVTN 080)...- Roche & Inovio Enter $422.5-Million Licensing Deal
Roche and Inovio Pharmaceuticals, Inc. recently announced they have entered into an exclusive worldwide license agreement to research, develop and...- INTRADERMAL DELIVERY – Advances in Intradermal Drug Delivery
Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.
- Peptineo Inks Exclusive Option for Drug Delivery Technologies
Peptineo recently announced the company has inked an exclusive option for a broad set of nanotechnology patents in the area...- Cobra Biologics & BioCancell Announce Agreement for Promising Cancer Therapy
Cobra Biologics and BioCancell recently announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials. BioCancell’s Phase I...- Latest Frost Reports: Next-Generation Therapeutics for Infectious Diseases; Orphan Drugs Market
Next-Generation Therapeutics The available antivirals for commonly occurring infections, such as respiratory syncytial virus (RSV) and influenza are characterized by...- Immune Response BioPharma to Develop In-House Sales Force for Blockbuster Vaccine
New Jersey-based Immune Response BioPharma, Inc. recently announced its plans to create an in-house sales force for Remune, its HIV...- Global Market for DNA Vaccines to Reach $2.7 Billion
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...- Global Market for DNA Vaccines to Reach $2.7 Billion
The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...- VACCINE TECHNOLOGY – Vaccine Technologies & the Rationale for New Nanoparticle Formulations
Robert S. Becker, PhD, MBA, and Mark A. Mitchnick, MD, explain how SATx technology provides a new flexible formulation platform for the generation of nanoparticulate vaccine formulations without the limitations of previous formulation technologies that have inhibited the optimization of vaccine potencies and safety profiles.
- DNA VACCINES MARKET – DNA Vaccines: Strategic Markets & Emerging Technologies
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
- NANOSCALE PARTICLES – VAULT: A Novel Nanofrontier in Drug Delivery
ABSTRACT Novel nanoscale particles (Vaults) as first described in 1986, exist in the multiples of thousands in most eukaryotic cells....- BIOTHERAPEUTICS DEVELOPMENT – The Role of Flow Electroporation in Vaccine Development
James Brady, PhD, Karen Donato, PhD, and Krista Steger, PhD, indicate that with unmatched quality, flexibility, and scalability, flow electroporation is a universal, cost-effective platform that supports the full range of biotherapeutic and vaccine development activities.
- DNA VACCINE TECHNOLOGY – A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
- EXECUTIVE INTERVIEW – ALTHEA: Giving Biopharmaceutical Companies the Power To Make
David Enloe, Althea’s President and CEO, discusses his company’s business strategy, why companies choose Althea, trends in the CMO industry, and how the company is growing since the acquisition of Ajinomoto.
- Astellas Pharma & Immunomic Therapeutics Announce $300-Million Worldwide Partnership for LAMP-vax Products
Immunomic Therapeutics, Inc. and Astellas Pharma Inc. recently announced they have entered into an exclusive worldwide license agreement to the...
VIDEO SPOTLIGHT
